Literature DB >> 18411198

Megestrol acetate-induced adrenal insufficiency.

Paula González Villarroel1, Isaura Fernández Pérez, Concepción Páramo, Marta Gentil González, Beatriz Carnero López, M Lidia Vázquez Tuñas, Juan A Carrasco Alvarez.   

Abstract

Megestrol acetate is a synthetic progestin that has been used since the 1970s for the treatment of advanced cancer and subsequently to treat anorexia, cachexia and weight loss in AIDS patients. It has been shown that high doses or prolonged treatment with this drug may cause Cushing's syndrome, new-onset diabetes and suppression of plasma ACTH and cortisol levels. Megestrol acetate may cause suppression of the pituitary-adrenal axis due to the affinity of this compound for the glucocorticoid receptor. Recognising the glucocorticoid-like activity of megestrol and its effects at the axis level is important for the diagnosis of sub-clinical adrenal insufficiency. We present the case of a 74-year-old woman with infiltrating ductal breast carcinoma refractory to prolonged hormonal treatment with megestrol acetate, presenting with adrenal insufficiency.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18411198     DOI: 10.1007/s12094-008-0188-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  8 in total

1.  Isolated corticotrophin deficiency presenting with pericardial effusion.

Authors:  F Pecori Giraldi; L M Fatti; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2005-10       Impact factor: 4.256

Review 2.  Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature.

Authors:  M Mann; E Koller; A Murgo; S Malozowski; J Bacsanyi; M Leinung
Journal:  Arch Intern Med       Date:  1997 Aug 11-25

3.  Clinical adrenal insufficiency in patients receiving megestrol therapy.

Authors:  S Subramanian; H Goker; A Kanji; H Sweeney
Journal:  Arch Intern Med       Date:  1997-05-12

4.  Megestrol acetate therapy and secondary adrenal suppression.

Authors:  K K Naing; J A Dewar; G P Leese
Journal:  Cancer       Date:  1999-09-15       Impact factor: 6.860

5.  A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer.

Authors:  P H Willemse; E van der Ploeg; D T Sleijfer; T Tjabbes; H van Veelen
Journal:  Eur J Cancer       Date:  1990-03       Impact factor: 9.162

6.  Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study.

Authors:  K M Rowland; C L Loprinzi; E G Shaw; A W Maksymiuk; S A Kuross; S H Jung; J W Kugler; L K Tschetter; C Ghosh; P L Schaefer; D Owen; J H Washburn; T A Webb; J A Mailliard; J R Jett
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

7.  A low-dose adrenocorticotropin test reveals impaired adrenal function in cancer patients receiving megestrol acetate therapy.

Authors:  I G Ron; V Soyfer; D Goldray; M J Inbar; Y Weisman
Journal:  Eur J Cancer       Date:  2002-07       Impact factor: 9.162

8.  The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients.

Authors:  M Dowsett; A Lal; I E Smith; S L Jeffcoate
Journal:  Br J Cancer       Date:  1987-03       Impact factor: 7.640

  8 in total
  2 in total

1.  Clinical Features and Risk Factors of Adrenal Insufficiency in Patients With Cancer Admitted to the Hospitalist-Managed Medical Unit.

Authors:  Min Kwan Kwon; Junhwan Kim; Jonghwa Ahn; Chang-Yun Woo; Hyeonjeong Kim; Hye-Seon Oh; Mingee Lee; Seungha Hwang; Keun Hoi Park; Young Hak Lee; Jakyung Yu; Sujeung Kang; Hyo-Ju Son
Journal:  J Korean Med Sci       Date:  2022-07-18       Impact factor: 5.354

Review 2.  Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia-Review and Expert Opinion.

Authors:  David C Currow; Matthew Maddocks; David Cella; Maurizio Muscaritoli
Journal:  Int J Mol Sci       Date:  2018-11-05       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.